Authors




By Cavit Boz, MD

Latest:

Real-World Data Highlight Teriflunomide Efficacy for RRMS

Teriflunomide was an effective first-line therapy for RRMS and a suitable switch therapy in real-world data.


Christoph Kaiser, MD

Latest:

Increased risk of major clinical events late after treatment with drug-eluting stents

We compared the incidence of late clinical events after withdrawal of clopidogrel between subjects treated with drug-eluting stents (DES) and those treated with bare-metal stents. Death and myocardial infarction occurred more frequently among DES-treated subjects during the follow-up period. The results of this study indicate that there may be a penalty for the lower rate of restenosis and reinterventions after DES implantation, in particular, an increased rate of late stent thromboses.




Adam Hochron

Latest:

Medical Ethics an Evolving Field with Long Reaching Implications

As the field of medical ethics continues to expand, its use can be seen in everything from general medical conditions to end of life considerations.


Colleen O'Leary, RN, MSN, AOCNS

Latest:

Expert Reasoning

Some families can be demanding, some questioning, some "overly concerned," but how often do we discount what they are saying because of the way they communicate with us?


Carolyn Colwell

Latest:

How a South African Boy with HIV Has Survived More Than Eight Years

“We ought to learn as much as we can about what makes these persons unique so we can find more therapeutic options that can be expanded to a larger population.”


Gary W. Jay, MD, FAAPM

Latest:

Some Thoughts Regarding the New Evidence-based Guidelines for Prevention of Episodic Migraine

A review of the guidelines published by the American Headache Society and the American Academy of Neurology (AAN) in the April 2012 issue of Neurology reveals some interesting surprises.



Jeff Kaplan, MD

Latest:

Being Healthy Is Not Just the Absence of Disease

The health and economic costs of poor lifestyle choices, poor health care planning, and misaligned incentives for care are the themes this week.


Dr. Scott Schumacher

Latest:

The Central or Non-Central Question: Identifying Patients Statewide

Determining the best way to identify patients statewide or nationally is one of the hottest topics of debate within today's health IT community.



James Miner, MD

Latest:

Sufentanil Sublingual Tablet Can Reduce Patient Reliance on IV Opioids

The soon-to-be marketed therapy Dsuvia has shown enough benefit, tolerability, and safety to aid an at-need patient population in a controlled setting.



Hiroshi Sat

Latest:

Prognosis of "masked" hypertension vs. "white-coat" hypertension

We compared the prognosis of patients with "white-coat" hypertension (WCHT) with that of patients with "masked" hypertension (MHT). The 10-year composite risk of stroke morbidity and cardiovascular mortality for patients with WCHT was similar to the risk for patients with sustained normal blood pressure, whereas the risk was markedly increased for patients with MHT and sustained hypertension. This indicates that conventional blood pressure measurements may fail to distinguish some patients at high or low risk.


Silas Inman
Silas Inman

Latest:

AI an Effective Geographic Atrophy Screening Tool

Retina specialists and an AI screening tool trained to measure geographic atrophy agreed in a majority of cases, potentially expediting clinical trial enrollment and increasing consistency in measuring the disease.


Sidney S. C. Wu, MD, FAAP

Latest:

Leprosy: Forgotten in America?

Leprosy was well recognized in antiquity and was often associated with social stigma. In 1873, Dr G. Hansen first identified Mycobacterium leprae as the cause for this condition, which was then named Hansen's disease. Not until the 20th century was specific treatment developed. Leprosy remains endemic to certain areas in the world, especially tropical and subtropical zones. Overall prevalence has decreased, but the reported incidence of leprosy has remained steady, even in the United States. In light of the significant morbidity associated with the disease, physicians must remain vigilant for its signs and symptoms even in developed countries, especially with increasing travel to and from endemic areas.


Carly Ornstein

Latest:

ALA Offers New Resources to IPF Patients

At the most recent American Lung Association LUNGFORCE expo, RDR sat down with Carly Ornstein to discuss the new resources made available by the ALA to individuals affected by lung fibrosis.



Mathew Maurer, M.D.

Latest:

Managing hATTR Amyloidosis

In an interview with Rare Disease Report, Mathew Maurer, MD, Arnold and Arlene Professor of Cardiology at Columbia University, explained the standard of care and current management tactics for individuals with hATTR Amyloidosis.


Louise Pilote, MD, MPH, PhD

Latest:

Angiotensin-converting enzyme inhibitors in elderly patients with acute myocardial infarction: A class effect?

Using a retrospective observational study design, we assessed whether all angiotensin-converting enzyme (ACE) inhibitors had similar mortality rates after acute myocardial infarction in patients aged 65 years or older. Our results showed that mortality rates for enalapril, fosinopril, captopril, and quinapril were higher than that for ramipril. This suggests that there is no class effect for ACE inhibitors. Further research is needed to confirm the results of our study.



Florence N. Hutchison, MD

Latest:

Ethnic differences in blood pressure control in men

We compared blood pressure control among white and African American hypertensive men in Veterans Affairs (VA) and non-VA sites, and found that the dis parity between the two ethnic groups was 40% less at VA sites. Better access to care and medications for African Americans at the VA sites may explain the difference.




Giacomo Levantesi, MD

Latest:

The prognostic role of metabolic syndrome after myocardial infarction

We evaluated the prognostic role of metabolic syndrome after myocardial infarction and found that metabolic syndrome correlated with an increased risk of cardiovascular events and death. The risk of developing diabetes decreased with weight loss in patients with metabolic syndrome. These results indicate that a more aggressive approach to the treatment of patients with metabolic syndrome, particularly with regard to changes in lifestyle, would be beneficial.


James R. Couch, MD, PhD

Latest:

Medication Overuse Headache: When the Cure is the Cause of the Pain

Also known as rebound headache, medication overuse headache is a fairly common condition that can be missed by non-specialists who are unfamiliar with its presentation and clinical signs. This article reviews the causes and types of medication overuse headache and discusses the current thinking on treatment.


Roger S. Blumenthal, MD

Latest:

Triglycerides and EPA: A New Chapter in CV Disease Prevention

Findings from REDUCE-IT are the first to show that EPA lowers the relative risk of hard cardiovascular endpoints. Johns Hopkins' Seth Martin, MD, and colleagues put the trial in perspective. 

© 2024 MJH Life Sciences

All rights reserved.